3 Key Takeaways From VIVUS' Earnings

Drugmaker VIVUS (NASDAQ: VVUS  ) reported its fourth-quarter earnings after the closing bell on Monday. Shares traded down 12% today; investors were clearly not impressed with the results.

Sales of the company's obesity drug Qsymia were the primary focus of the report, but what else should investors be paying attention to when they analyze VIVUS' quarter? In this video, health care analyst Max Macaluso discusses three essential topics that investors need to consider.

Is now the time to sell VIVUS?
VIVUS' shares were clobbered after Qsymia's dismal launch. Investors everywhere are wondering whether the tide will turn for this fledgling drugmaker or if now is the perfect time to sell. In a new premium research report, the Fool's top health care contributor breaks down this complex story and explains the details VIVUS investors must know -- including reasons to buy and sell. To find out more about this premium report -- complete with a full year of free updates -- click here now.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2279945, ~/Articles/ArticleHandler.aspx, 7/25/2014 1:04:16 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement